author-photo

Wael Hozaeel

9

Papers

390

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

2016 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (315)
Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial.

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (17)
IMAB362 plus zoledronic acid (ZA) and interleukin-2 (IL-2) in patients (pts) with advanced gastroesophageal cancer (GEC): Clinical activity and safety data from the PILOT phase I trial.

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (The QoLiTax-Trial of the Arbeitsgemeinschaft Internistische Onkologie, AIO).

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Interim analysis of a phase I/II open label, dose-escalating study to investigate safety, tolerability, and preliminary efficacy of the trifunctional anti-HER2/neu x anti-CD3 antibody ertumaxomab in patients with HER2/neu expressing solid tumors progressing after standard therapy.

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Combination of Trastuzumab and Triple FLOT Chemotherapy (5-Fluorouracil/Leucovorin, Oxaliplatin, and Docetaxel) in Patients with HER2-Positive Metastatic Gastric Cancer: Report of 3 Cases

2012 Onkologie
Show All
- Source
- Cite
- Save
Citations (8)